PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Duke-NUS study targets proteins to reverse lung scarring

Duke-NUS researchers have identified that blocking specific proteins in immune cells can significantly reduce or reverse lung scarring. This discovery paves the way for novel treatments that could potentially reverse damage from pulmonary fibrosis.

2025-02-20
(Press-News.org) Singapore, 20 February 2025—A discovery at Duke-NUS Medical School offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in immune cells that, when blocked, could significantly reduce lung tissue scarring.

Current treatments primarily manage symptoms and improving quality of life, without addressing the underlying cause of pulmonary fibrosis.

Although macrophages, a type of immune cell, had previously been known to contribute to inflammation and scarring in pulmonary fibrosis, the underlying mechanisms remained unclear. After discovering that two proteins in macrophages—YAP and TAZ—are involved in heart scarring, researchers from the School sought to determine whether these proteins play a similar role in the lungs and to better understand how their activity influences disease progression.

YAP and TAZ are part of a critical molecular pathway that usually helps cells grow and repair. However, in a preclinical model of pulmonary fibrosis, the researchers discovered that these proteins can also contribute to harmful scarring.

In their study, published in the European Respiratory Journal, the researchers found that blocking YAP and TAZ can curb scar formation and restore the immediate environment to one that encourages regeneration in three ways:

Dampening a loud call to arms: YAP and TAZ drive inflammation by amplifying the effect of a molecule called CCL2. Like a homing beacon, this signalling molecule attracts various immune cells to the affected areas of the lungs during injuries. However, when recruited to the lungs in excess, these immune cells can harm the organs by causing uncontrolled inflammation, leading to tissue scarring. Disrupting the connection between the two proteins and CCL2 reduces the number of immune cells recruited, impeding tissue scarring.

Maintaining a healthy immune cell ratio: YAP and TAZ can harm the lungs by increasing inflammatory immune cell levels, amplifying tissue inflammation. When these proteins are removed, immune cells that help to repair and regenerate damaged tissue outnumber their inflammatory counterparts, reducing lung inflammation and allowing the organ to heal more effectively.

Disrupting the proteins’ communication with a nearby pathway: These proteins can also exacerbate pulmonary fibrosis by influencing macrophages’ interaction with fibroblasts, which are nearby cells that are key to repairing damaged tissue and maintaining organ structure. Unregulated macrophage activity excessively signals fibroblasts to respond to an injury in the lungs, leading to tissue scarring. Inhibiting YAP and TAZ interrupts the communication between macrophages and fibroblasts, reducing damage to the lungs.    

Principal Research Scientist Dr Md Masum Mia from Duke-NUS’ Cardiovascular and Metabolic Disorders Programme, the study’s first author, said of the findings:

“This breakthrough not only deepens our understanding of the specific molecular mechanisms responsible for pulmonary fibrosis, but could also lead to treatments that halt or even reverse lung scarring in the disease.”

Paving the way for new treatment options for pulmonary fibrosis

Global early-phase clinical trials for novel therapies that target YAP and TAZ in cancers, which are characterised by immune-driven inflammation and scarring, are underway, and the research team is exploring if such therapies are viable for treating patients with pulmonary fibrosis.

Associate Professor Manvendra Kumar Singh from Duke-NUS’ Cardiovascular and Metabolic Disorders Programme, the study’s senior author, said of the next steps for the project:

“Pulmonary fibrosis is strongly linked to the unregulated activity of immune and connective tissue cells as well as the loss of epithelial cells. By delving into these interactions that drive tissue scarring, we can gain deeper insights and uncover potential therapeutic targets for treatment. Next, we will further validate the roles of YAP and TAZ in the disease and confirm the effectiveness of therapies that inhibit these proteins, offering patients better outcomes.”

In addition to pulmonary fibrosis, YAP and TAZ are also implicated in heart, liver and kidney fibrosis, suggesting that therapies targeting these proteins could offer broader therapeutic potential for a range of fibrotic diseases.

Professor Patrick Tan, Senior Vice-Dean for Research at Duke-NUS, commented:

“By focusing on the root causes of fibrosis, our novel therapeutic approach offers the potential not just to manage but to significantly halt or reverse the progression of pulmonary fibrosis. This breakthrough could dramatically improve patient outcomes, reduce long-term healthcare costs, and ultimately enhance life expectancy and quality for sufferers globally.”

This new research, part of Duke-NUS’ efforts to develop biomedical solutions that improve the lives of patients, is supported by the National Research Foundation, Singapore under the National Medical Research Council (NMRC) Open Fund-Individual Research Grant (MOH-001625) and the Open Fund-Young Individual Research Grant (MOH-001130) and administered by the Singapore Ministry of Health through the NMRC Office, MOH Holdings Pte Ltd.

 

###
 

DOI: 10.1183/13993003.01544-2023

 

 

About Duke-NUS Medical School

Duke-NUS is Singapore’s flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted ‘Clinicians Plus’ poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten Centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore’s largest healthcare group. This strategic alliance has led to the creation of 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives.   

For more information, please visit www.duke-nus.edu.sg 

 

About the National Medical Research Council (NMRC)

The NMRC was established in 1994 to oversee research funding from the Ministry of Health and support the development and advancement of biomedical research in Singapore, particularly in the public healthcare clusters and medical schools. NMRC engages in research strategy and planning, provides funding to support competitive research grants and core research enablers, and is responsible for the development of clinician scientists through awards and fellowships. The council’s work is supported by the NMRC Office which is part of MOH Holdings Pte Ltd. Through its management of the various funding initiatives, NMRC promotes healthcare research in Singapore, for better health and economic outcomes.
 

For media enquiries, please contact:

Brandon Raeburn
Communications
Duke-NUS Medical School
Tel: +65 9776 8496
Email: braeburn@duke-nus.edu.sg

END



ELSE PRESS RELEASES FROM THIS DATE:

New toolkit empowers healthcare providers with evidence-based strategies for childhood obesity prevention and treatment

New toolkit empowers healthcare providers with evidence-based strategies for childhood obesity prevention and treatment
2025-02-20
Greaux Healthy—a public service initiative powered by Pennington Biomedical Research Center, in partnership with the State of Louisiana—is proud to announce the release of the Childhood Obesity Prevention, Evaluation and Treatment Toolkit, a comprehensive resource designed to equip healthcare providers with practical, evidence-based guidance for preventing, evaluating, and treating childhood obesity and its related comorbidities. Developed in alignment with the 2023 American Academy of Pediatrics (AAP) clinical practice guidelines, the toolkit synthesizes the latest scientific evidence and ...

UT MD Anderson and Texas Children’s Hospital announce joint venture to end childhood cancer

2025-02-20
HOUSTON ― The University of Texas MD Anderson Cancer Center and Texas Children’s Hospital have announced a transformational collaboration dedicated solely to pediatric cancer care. Approved by the UT System Board of Regents and the Texas Children’s Board of Trustees, this new, first-of-its-kind joint venture will unite the nation’s largest comprehensive pediatric system and a top pediatric cancer program with the nation’s leading comprehensive cancer center. The collaboration has a single ...

Texas Children’s Hospital and UT MD Anderson announce joint venture to end childhood cancer

2025-02-20
HOUSTON, TX (February 19, 2025) – Texas Children’s Hospital and The University of Texas MD Anderson Cancer Center have announced a transformational collaboration dedicated solely to pediatric cancer care. Approved by the Texas Children’s Board of Trustees and the UT System Board of Regents, this new, first-of-its-kind joint venture will unite the nation’s largest comprehensive pediatric system and a top pediatric cancer program with the nation’s leading comprehensive cancer center. The collaboration has a single mission: to end childhood cancer. “The scope and scale of our combined effort will build the world’s preeminent pediatric cancer ...

New medication sinus thrombosis just as safe but more patient-friendly

2025-02-20
Patients affected by sinus thrombosis are treated with blood thinners. Traditionally, these patients are prescribed vitamin K antagonists (VKAs). In order to give the correct dosage, regular check-ups at the thrombosis service are necessary. A global study, coordinated by Amsterdam UMC, now shows that new medication, direct oral anticoagulants (DOACs), are equally safe and effective. The study was published today in The Lancet Neurology.  A big advantage is that this medication is more user-friendly because regular thrombosis monitoring is no longer ...

About 740,000 global deaths from suicide occur annually--that's one death every 43 seconds

2025-02-20
Every minute, four males and six females need inpatient treatment due to suicide attempts around the world. Males die from suicide at twice the rate of females, and their attempts result in death three times more often than female attempts. Globally, 10% of suicides by males and 3% by females were with guns. In the U.S., 55% by males and 31% by females were with guns. Between 1990 and 2021, the global age-standardized death rate for suicide declined by almost 40%, indicating that intervention and prevention are ...

Experts strongly recommend against spine injections for chronic back pain

2025-02-20
Spine injections should not be given to adults with chronic back pain because they provide little or no pain relief compared with sham injections, say a panel of international experts in The BMJ today. Their strong recommendations apply to procedures such as epidural steroid injections and nerve blocks for people living with chronic back pain (lasting at least 3 months) that is not associated with cancer, infection or inflammatory arthritis. Their advice is based on the latest evidence and is part of The BMJ’s ‘Rapid ...

Racism in medicine - are things getting better?

2025-02-20
Five years on since The BMJ’s special issue on racism in medicine, and a global pandemic, the landscape is very different, but has racism in the NHS and UK medicine got better or worse? In 2020, a BMJ investigation found that UK medical schools were failing to deal with complaints of racism. Another round of requests to the UK’s 46 medical schools has now found that eight in 10 (34 of 41 that responded) are collecting data on complaints about racism, up from half in 2020. And the number ...

Forcing UK creatives to ‘opt out’ of AI training risks stifling new talent

2025-02-20
The UK government should resist allowing AI companies to scrape all copyrighted works unless the holder has actively “opted out”, as it puts an unfair burden on up-and-coming creative talents who lack the skills and resources to meet legal requirements. This is according to a new report from University of Cambridge experts in economics, policy and machine learning, who also argue the UK government should clearly state that only a human author can hold copyright – even when AI has been heavily involved. A collaboration between three Cambridge initiatives – ...

Almost 90% of people would agree to genetic testing to tailor medication use, survey finds

2025-02-20
New research shows almost 90% of people in England would agree to genetic testing to get the most effective medication and reduce the risk of side effects 85% thought that the NHS should offer pharmacogenomic testing to people with multiple health conditions 58% of people thought that the NHS should offer this testing to everyone 91% wanted access to their own pharmacogenomic data, with many wanting this via the NHS app Pharmacogenomics – an individual’s genetic response to medications – is an increasingly important strand of personalised healthcare but little is known about the public's views ...

Study: UTA research drives widespread economic impact

Study: UTA research drives widespread economic impact
2025-02-19
University of Texas at Arlington research projects contributed $59 million to the national economy in 2024—an increase of 39% from 2023, according to a new report from the Institute for Research on Innovation and Science (IRIS). UTA has invested heavily in research infrastructure, purchasing cutting-edge scientific equipment and technology, such as North Texas’ most advanced gene sequencer and a super-sensitive magnetic resonance imaging machine for the Clinical Imaging Research Center. The funds also support collaboration with other research organizations. UTA worked through 1,144 unique ...

LAST 30 PRESS RELEASES:

Sugar-coated ‘sticky’ stem cells could unlock surgery-free liver treatments

Children’s social media activity highlights emotional stress of living with long-term health issues

New tool maps hidden roles and risks in ecosystems

New breakthrough method to protect quantum spins from noise

Chemicals from turmeric and rhubarb could help fight antibiotic-resistant bacteria lurking in wastewater

Instant cancer diagnosis with light and AI!

New electroenzymatic strategy enables non-natural oxidation reactions

Tunable laser light

Scientists uncover magnetic-field control of ultrafast spin dynamics in 2D ferromagnets

New AI-powered model accurately predicts lung motion with minimal radiation

AI language models show promise in predicting liver cancer treatment outcomes

Tracking insect and bug health in a heartbeat from a digital camera

'Talking fish' not heard by conservation policies, SFU study warns

Thirty years of research shows increased resistance in fungi

Junk food ‘avoids advertising regulation’ with top level UK sports sponsorship

Banking on AI while committed to net zero is ‘magical thinking’, claims report on energy costs of big tech

Ancient river systems reveal Mars was wetter than we thought

Online toolkit to help parents of autistic children improve dental health

The psychological and neurological parallels between sports fandom and religious devotion

Agricultural liming in the US is a large CO2 sink, say researchers

Seaside more likely to make us nostalgic than green places, study finds

Psilocybin delays aging, extends lifespan, Emory study suggests

Buck Institute awarded DARPA contract to pioneer next-gen AI modeling platform

Orange is the new aphrodisiac—for guppies

Murals boost Cincinnati’s vitality, community development

Ad blockers may be showing users more problematic ads, NYU Tandon study finds

Verbal response time reveals hidden sleepiness in older adults

University of Maryland School of Medicine launches groundbreaking study on THC/CBD therapy for dementia-related agitation at end of life

Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery

SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts

[Press-News.org] Duke-NUS study targets proteins to reverse lung scarring
Duke-NUS researchers have identified that blocking specific proteins in immune cells can significantly reduce or reverse lung scarring. This discovery paves the way for novel treatments that could potentially reverse damage from pulmonary fibrosis.